A tethered yeast surface display construct is designed that leverages high local concentrations by tethering a candidate protein binder to a target protein of interest (POI) via a flexible peptide linker to demonstrate that epitope-specific screening and enrichment is possible based on fluorescent output and study key optimization parameters.
Abstract
Abstract Engineering proteins for therapeutic applications is a field that has seen substantial growth in the past two decades, but challenges remain. A major deficiency in current strategies is the lack of a means to efficiently screen for binding to key epitopes to yield a desired function. To meet this challenge, we designed a tethered yeast surface display construct that leverages high local concentrations by tethering a candidate protein binder to a target protein of interest (POI) via a flexible peptide linker. These high local concentrations enable screening of epitope-specific binders based on decreased signal due to inhibitory function when the construct is assayed alongside a competitive POI binder. We demonstrate that epitope-specific screening and enrichment is possible based on fluorescent output and study key optimization parameters. We anticipate this technique will accelerate binder development by reducing the need for downstream low throughput epitope mapping of isolated proteins.
A protocol for discovering protein‐binding peptides using a very large, target‐agnostic yeast surface display library containing approximately 6.1 × 109 unique clones and providing broad coverage of short peptide sequence space is described.
J. D. Hurley, Andrew C. Kruse· Current Protocols· 0 citations
This work presents a scalable mammalian cell-display workflow to identify AI-designed minibinders against cancer surface targets and identifies biochemical optimization beyond the binding interface as a critical requirement for translating AI-minibinders into functional applications.
B. Broske, B. McEnroe, S. C. Frechen et al.· Nature Communications· 1 citation
This framework synthesizes generative protein design workflows to screen 1,758 newly designed protein binders targeting BCMA, CD19 and CD22 for efficacy in scalable protein-binding, T-cell activation and in vivo killing assays, and develops computational and experimental heuristics to overcome limitations.
Arthur Chow, Ho-Yin Chu, Ruo-Fan Li et al.· Nature Biomedical Engineerin...· 0 citations
The concept of mimic antibodies–antibodies that recapitulate the binding mode of a target’s cognate ligand is investigated and established as a promising strategy for rational antibody selection, engineering, and design, with broad implications for therapeutic antibody development and drug discovery.
Brennan Abanades, Joanan López-Morales, Ivana Tanasijević et al.· mAbs· 2 citations
“Undruggable” proteins without surface-accessible binding sites pose significant challenges to target-based drug discovery. Innovative approaches are needed to tackle these proteins. One promising strategy is targeting them in their nascent chain form at the ribosome, where they have a different conformation than in th...
P. Fischer, Sebastian Hiller· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.